Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 248.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 43,539 shares of the company's stock after buying an additional 31,037 shares during the quarter. Intech Investment Management LLC owned 0.14% of Fulgent Genetics worth $804,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Fulgent Genetics by 803.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company's stock valued at $2,326,000 after purchasing an additional 112,011 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Fulgent Genetics by 314.7% during the fourth quarter. AlphaQuest LLC now owns 35,692 shares of the company's stock worth $659,000 after purchasing an additional 27,085 shares in the last quarter. Amundi increased its holdings in Fulgent Genetics by 143.7% in the fourth quarter. Amundi now owns 8,816 shares of the company's stock valued at $166,000 after buying an additional 5,199 shares during the last quarter. Aigen Investment Management LP acquired a new stake in Fulgent Genetics in the fourth quarter valued at $217,000. Finally, Proficio Capital Partners LLC purchased a new stake in Fulgent Genetics during the 4th quarter worth about $411,000. Institutional investors and hedge funds own 48.06% of the company's stock.

Insider Activity at Fulgent Genetics

In other news, CFO Paul Kim purchased 100,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the purchase, the chief financial officer now directly owns 348,282 shares of the company's stock, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 31.76% of the stock is currently owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on FLGT shares. StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th. Piper Sandler cut their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th.

Fulgent Genetics Stock Performance

NASDAQ FLGT traded down $0.05 during trading hours on Thursday, hitting $16.85. The company had a trading volume of 355,634 shares, compared to its average volume of 232,801. The company has a market cap of $519.47 million, a PE ratio of -3.05 and a beta of 1.54. Fulgent Genetics, Inc. has a 1-year low of $14.57 and a 1-year high of $25.11. The business has a 50 day moving average of $16.82 and a 200-day moving average of $18.73.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.